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Calcium acetate, an effective phosphorus binder in patients with renal
failure. Calcium salts are increasingly used as phosphorus binders in
patients with chronic renal failure. Calcium carbonate is the principal
salt presently utilized, however, other calcium salts may be more
effective and safer phosphorus binders. Theoretical calculations, in
vitro experiments, and in vivo studies in normal subjects have shown
calcium acetate to be a more effective phosphorus binder than other
calcium salts. This salt has not previously been studied in patients with
chronic renal failure. We used a one-meal gastrointestinal balance
technique to measure phosphorus absorption, calcium absorption and
phosphorus binding in six patients with chronic renal failure. Calcium
acetate was compared with calcium carbonate and placebo. Equivalent
doses (50 mEq Ca') of calcium acetate bound more than twice as
much phosphorus (106 23 mg) as calcium carbonate (43 39 mg) P
<0.05. When phosphorus binding was factored for calcium absorption,
calcium acetate bound 0.44 mEq HP04/mEq absorbed Ca+* com-
pared with 0.16 mEq HP04 bound/mEq Ca absorbed with calcium
carbonate. More efficient phosphorus binding permits serum phospho-
rus concentration to be controlled with lower doses of calcium salts.
The higher phosphorus binding/calcium absorption ratio coupled with a
lower dose indicates that less calcium will be absorbed when calcium
acetate is used for phosphorus control. Markedly positive calcium
balance, hypercalcemia and ectopic calcification should be less likely to
occur with this drug than other calcium salts.
Patients with chronic renal failure can absorb toxic quantities
of aluminum when aluminum salts are ingested as phosphorus
binders [1—8]. This relatively recent discovery has accelerated
the search for alternative safe and effective, aluminum-free
phosphorus binders. Calcium carbonate is the most widely
used, non-aluminum phosphorus binding salt [9—12]. However,
large doses of calcium carbonate are often necessary to achieve
adequate control of serum phosphorus concentrations. The
ingestion of such large quantities of calcium enhances its
absorption and can result in hypercalcemia and ectopic calcifi-
cation [10—13].
Theoretical calculations, using well-defined equilibrium con-
stants, suggested that calcium acetate should be an effective
phosphorus binder [14]. In vitro experiments confirmed these
theoretical calculations [141. Subsequent in vivo studies in
Received for publication December 27, 1988
and in revised form May 4, 1989
Accepted for publication May 9, 1989
© 1989 by the International Society of Nephrology
normal subjects found calcium acetate to be a more potent
phosphorus binder than either calcium carbonate or calcium
citrate [14].
Calcium acetate has not previously been studied in patients
with chronic renal failure. We used a one-meal gastrointestinal
washout technique to measure gastrointestinal phosphorus and
calcium absorption from the meal [15, 16]. We then compared
phosphorus binding by calcium acetate with calcium carbonate
and placebo. A randomized double-blind protocol was utilized.
Methods
Subjects
We studied six subjects with end-stage renal disease who
received chronic maintenance hemodialysis (approximately 4
hrs, 3 times per week). Three subjects were men and three were
women. Age range was 39 to 62 years, with a mean age of 52
years. Each patient was medically stable. Patient #3 (Table 1)
had been previously treated for aluminum bone disease with
desferoxamine. The drug was stopped six months prior to the
initiation of this study. Patient #6 was receiving oral 1 ,25(OH)2
vitamin D3, 0.75 zg/day. Patients were studied between dialysis
days.
The study was approved by the Institutional Review Board
for Human Protection of Baylor University Medical Center. All
subjects were paid a fee for taking part in these experiments.
Informed written consent was obtained from each subject.
Materials
Calcium salts were provided in gelatin capsules containing
500 mg of calcium acetate and 315 mg of calcium carbonate
(each equivalent to 125 mg of elemental calcium per capsule).
Placebo contained 540 mg of lactose. The capsules were man-
ufactured by Lyne Laboratories of Stoughton, Massachusetts
for Braintree Laboratories, of Braintree, Massachusetts, USA.
The meal consisted of 80 g of ground sirloin steak seasoned
with salt and pepper, 30 g of swiss cheese, 100 g of french fried
potatoes, and 250 ml water. Test meals were prepared each day
in duplicate: one meal to be ingested by the subject and the
other to be analyzed for phosphorus and calcium. On average,
the meals contained 346 mg of phosphorus, and 201 mg of
calcium. Ten g of polyethylene glycol (PEG) dissolved in the
water was ingested with the meal and served as a nonabsorbed
marker.
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Table 1. Patient demographics and serum chemistry
Serum l,25(OH)
Serum [Ca] Serum [P1 vit D
Months on rng/dl mg/dl pg/rn!
Patient Age Sex dialysis (nI 8.5—10.5) (nI 2.5—4.5) (nI 10—60)
1 54 F 5 10.1 4.9 8
2 47 F 126 7.9 4.9 5
3 55 F 111 11.6 7.6 5
4 62 M 59 8.8 5.2 5
5 41 F 37 10.3 2.2 5
6 39 M 15 10.2 7.2 9
The poorly-absorbed lavage fluid used in this study has been
previously described [15]. It contained 40 mmol Na2SO4, 25
mmol NaCI, 20 mmol NaHCO3, 10 mmol KCI and 80 mmol
mannitol.
Procedure
The method used to measure calcium and phosphorus ab-
sorption from a single meal has been previously described [16].
Subjects reported to the laboratory on a nondialysis day after an
eight hour fast. Blood was drawn for baseline analysis of
phosphorus, calcium and l,25(OH)2 vitamin D3 on the first
study day.
Each subject was studied on four separate test days: I. fast;
2. meal plus placebo; 3. meal plus calcium acetate (I g elemental
calcium); 4. meal plus calcium carbonate (I g elemental calci-
um). The test day sequence was randomized.
On each study day the gastrointestinal tract was thoroughly
cleansed by lavage using the poorly absorbed solution. Four
hours after this cleansing lavage, subjects ingested one-half of
the total dose of calcium salt, or placebo, together with 100 ml
of deionized water. This was immediately followed by the
standard meal and then the remaining half dose of calcium salt
or placebo. After a ten-hour absorption period, the GI tract was
again lavaged to remove unabsorbed dietary constituents and
calcium salt. The rectal effluent was quantitatively collected for
measurement of calcium, phosphorus, and PEG. On the fast
day, the procedure was identical except neither a meal nor
calcium salt was ingested.
Duplicate meals, capsules and rectal effluent were analyzed
for calcium by atomic absorption spectroscopy and for phos-
phorus by the method of Fiske and Subbarow [17]. PEG was
analyzed by the method of Hyden [181. Each specimen was
analyzed in duplicate. l,25(OH)2 vitamin D3 levels were mea-
sured by Nichols Institute, San Juan Capestrano, California,
USA.
Analysis and calculations
Net absorption of phosphorus is calculated using the follow-
ing equation:
Net phosphorus
— phosphorus (effluent phosphorus effluent phosphorus
absorption — ingested
—
after meal
—
after fast
The rectal effluent collected after the fast contained that
phosphorus which had moved down a concentration gradient
into the initially phosphorus-free lavage fluid. Thus, it repre-
sented the amount of phosphorus in the effluent which was
attributable to the lavage procedure itself. This quantity was
then subtracted from the effluent phosphorus collected follow-
ing a meal to calculate the amount of ingested phosphorus
which had escaped absorption.
Phosphorus binding by each calcium salt was calculated using
the following equation:
Phosphorus binding =
Phosphorus absorbed Phosphorus absorbed from
from meal ingested — meal ingested with binding
with placebo salt
Calcium absorption from the meal and from the meal plus
calcium salt was calculated using analogous equations except
that calcium intake included both the calcium in the meal and
that in the capsules.
To compare phosphorus binding potency of calcium salts the
ratio phosphorus bound/calcium ingested was calculated. Each
measurement was converted to milliequivalents so that compa-
rable units were used. The major calcium-phosphate precipitate
which forms in the intestine is probably CaHPO4. Therefore, a
phosphate valance of 2 was used. Milligrams of phosphorus are
converted to milliequivalents of HPO4 by the multiplication
factor of (1 mmol/3 1mg) (2 mEq/mmol) = 0.0645 mEq/mg.
To compare salts on the basis of phosphorus bound per unit
calcium absorbed, the ratio mEq HP04 bound/mEq Ca
absorbed was calculated.
Results
Patient demographics, baseline serum calcium, inorganic
phosphorus and 1 ,25(OH)2 vitamin D3 levels are shown in Table
I. Although patient #6 was receiving oral 1 ,25(OH)2 vitamin D3
0.75 tg/day, his serum level remained subnormal.
On each test day the rectal effluent collected after the second
lavage was analyzed for PEG to determine whether the nonab-
sorbed dietary constituents were completely recovered. Com-
bined PEG recovery for all studies was 100.5 0.7% (mean
5EM; range: 93 to 111%). This indicates that excellent recovery
was achieved.
Phosphorus and calcium absorbed from the meal alone and
the meal plus calcium salt are shown in Tables 2 and 3. When
the meal was ingested with placebo the subject absorbed 181
31 mg (mean SEM) of phosphorus or 53% of the ingested load.
The subjects did not absorb calcium but instead showed net
calcium secretion of 28 28 mg.
When calcium carbonate (1 g, or 50 mEq, of elemental
calcium) was administered with the meal, phosphorus absorp-
tion fell to 138 21 mg or 40% of the ingested load. Therefore,
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Table 2. Intake, effluent output and absorption of phosphorus in patients with chronic renal failure
Fast Placebo CaCO3 Ca acetate
Out In Out Abs In Out Abs In Out Abs
mg
1 212 342 432 122 348 349 211 345
2 91 342 91 342 322 271 142 361
3 29 332 235 126 338 293 74 325
4 139 343 323 159 350 331 158 341
5 54 352 263 143 350 336 68 350
6 83 362 254 191 339 248 174 356
512
319
303
375
383
343
45
133
51
105
21
96
Mean 101 346 266 181 341 305 138 346
SEM 25 4 42 31 4 15 21 5
373
28
75
16
Abbreviations are: In, ingested; Out, recovered; Abs, absorbed.
Table 3. Intake, effluent output and absorption of calcium in patients with chronic renal failure
Fast Placebo CaCO3 Ca acetate
Out In Out Abs In Out Abs In Out Abs
mg
1 171 202 536 —163 1209 1202 178 1218
2 91 210 319 —18 1221 949 363 1226
3 51 208 319 50 1200 922 329 1192
4 115 177 276 16 1180 769 526 1189
5 61 193 301 —47 1176 796 441 1176
6 89 216 309 —4 1197 994 292 1212
1190
956
980
844
843
1096
199
361
263
460
394
205
Mean 101 201 325 —28 1197 939 355 1202
SEM 16 5 42 28 6 59 46 7
985
52
314
41
Abbreviations are: In, ingested; Out, recovered; Abs, absorbed; (—) sign indicates net secretion.
calcium carbonate bound 43 mg of phosphorus (181 mg — 138
mg). Calcium absorption from the meal plus calcium carbonate
was 355 46 mg or 30% of the total ingested calcium load. The
phosphorus binding ratios were 2.8 mEq HP04 bound/SO mEq
Ca ingested or 0.06 mEq HP04 bound/mEq Ca ingested.
Factoring phosphorus binding for calcium absorption shows 2.8
mEq HPO4 are bound while 17.8 mEq Ca are absorbed
yielding a ratio of 0.16 mEq HP04 bound/mEq Ca + ab-
sorbed.
An equivalent quantity of calcium acetate ingested with the
meal reduced phosphorus absorption to 75 16 mg or 21.7% of
the ingested load. Therefore, calcium acetate bound 106 mg of
phosphorus (181 mg — 75 mg). This is significantly greater than
the amount of phosphorus bound by calcium carbonate (P <
.05; Fig. 1). Calcium absorption from the meal plus calcium
acetate was 314 41 mg or 26% of the ingested calcium load.
Therefore, 6.9 mEq HP04 were bound by SO mEq of ingested
calcium yielding a ratio of 0.14 mEq HPO4 bound/mEq
calcium ingested. Factoring phosphorus binding for calcium
absorption shows that 6.9 mEq HP04 were bound for 15.7
mEq calcium absorbed or 0.44 mEq HP04 bound/mEq Ca
absorbed.
Discussion
Patients with chronic renal failure are usually vitamin D
deficient and also develop resistance to the action of vitamin D.
Vitamin D deficiency and resistance have greater effects on
intestinal calcium absorption than intestinal phosphorus ab-
sorption. The active component of calcium absorption falls
markedly so that calcium absorption from a normal diet may
cease or calcium secretion may occur. In contrast, patients with
vitamin D deficiency continue to absorb a large fraction of
ingested phosphorus.
We have previously studied phosphorus and calcium absorp-
tion from a standard meal in normal subjects using the gastro-
intestinal washout technique [141. When normal subjects in-
gested a cheeseburger and french fries meal, containing 342 mg
of phosphorus and 214 mg of calcium, they absorbed 77% of the
phosphorus load and 20% of the calcium load. Our subjects with
renal failure, studied with an identical technique and similar
meal, absorbed 53% of ingested phosphorus but showed net
calcium secretion.
Patients with modest renal failure can continue to absorb a
large fraction of ingested phosphorus and yet maintain balance
because secondary hyperparathyroidism develops and in-
creases renal phosphorus excretion. However, this mechanism
becomes inadequate when renal failure becomes severe. Main-
tenance of phosphorus balance at this stage requires a major
reduction of phosphorus intake and/or the use of phosphorus
binders to decrease gastrointestinal phosphorus absorption.
Phosphorus binding has for many years been accomplished
by the ingestion of aluminum-based binding salts. Recently the
toxicity of aluminum binding salts has been identified [1—8].
Consequently, other metal salts have replaced aluminum as
phosphorus binders. A variety of calcium and magnesium salts
have been utilized. In this study, we compared phosphorus
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Fig. 1. Phosphorus binding by calcium acetate and calcium carbon-
ate. Binding was calculated as the difference between phosphorus
absorption with placebo and phosphorus absorption with each salt. One
gm of elemental calcium (50 mEq) was ingested with the meal. Phos-
phorus binding by calcium acetate is significantly greater than binding
by calcium carbonate (P < 0.05).
binding by calcium acetate with calcium carbonate in patients
with chronic renal failure.
Calcium acetate (50 mEq elemental calcium) ingested with a
meal containing about 345 mg of phosphorus bound more than
twice as much phosphorus as calcium carbonate (106 mg vs. 43
mg). Converting to milliequivalent units and factoring phospho-
rus binding for ingested binder dose shows that 50 mEq of Ca ÷
ingested as the carbonate salt bound 2.8 mEq of phosphate
(calculated as HP04). This yields a ratio of 0.06 mEq of
HPO4 bound/mEq of Ca ingested. Similar calculations for
calcium acetate yield a ratio of 0.14 mEq HPO4 bound/mEq
Ca ingested. Both calcium salts are relatively inefficient
binders. Although calcium acetate is more potent, only 14% of
its potential phosphorus binding capacity is actually used to
bind phosphorus (see below). Therefore, dietary phosphorus
restriction remains a critical therapeutic cornerstone in patients
with renal failure.
When subjects ingest low to normal amounts of calcium,
intestinal calcium absorption is primarily accomplished via
vitamin D dependent, or active, transport mechanisms. At such
levels of calcium intake intestinal calcium absorption is linearly
correlated with the serum 1,25 dihydroxyvitamin D levels [191.
However, when calcium intake is supplemented with ingested
calcium salts, calcium absorption becomes less dependent on
vitamin D activated mechanisms. When the luminal calcium
concentration is increased to levels which saturate vitamin D
dependent mechanisms, additional calcium absorption is ac-
complished by vitamin D independent, or passive, mechanisms.
Therefore, despite low, or undetectable, vitamin D levels large
amounts of calcium are absorbed when calcium supplements
are administered.
The ingestion of I g of calcium, as the acetate salt, together
with the meal resulted in the absorption of314 mg of calcium, or
26% of the ingested load. Similarly, ingestion of 1 g of calcium
as the carbonate salt together with the meal resulted in the
absorption of 355 mg of calcium, or 30% of the ingested load.
The fraction of calcium which does not bind phosphorus, may
combine with other dietary constituents, be absorbed, or be
excreted in the stool in the form of the ingested salt. Systemic
absorption of the salt can have either beneficial or toxic
consequences. Patients with chronic renal failure are often in
chronic net negative calcium balance and could therefore
benefit from calcium supplementation. Indeed, dialysis solu-
tions are usually designed to insure positive calcium balance
during the dialytic period. However, excessive calcium absorp-
tion can produce hypercalcemia and ectopic calcification. The
quantity of calcium absorbed in our study (26 to 30% of load)
suggests that excessive calcium absorption may occur when
these salts are used chronically. Therefore, calcium salts which
are preferentially utilized to bind phosphorus and can be used in
lower doses may be advantageous.
In view of the above considerations, calcium salts can be
compared as phosphorus binders on the basis of quantity of
phosphorus bound per unit of calcium absorbed. This calcula-
tion yields a ratio of 0.44 mEq of HP04 bound/mEq Ca
absorbed when calcium acetate is used. This compares with
0.16 mEq HP04 bound/mEq Ca + absorbed when calcium
carbonate is utilized. On this basis, calcium acetate is almost
three times more efficient than calcium carbonate. To achieve
equal binding of phosphorus a smaller dose of calcium acetate
than calcium carbonate can be used and less calcium will be
absorbed.
Why is calcium acetate a more effective phosphorus binder
than calcium carbonate? Calcium acetate is readily soluble in
both acid and alkaline solutions. In vitro it rapidly and effi-
ciently binds phosphorus in the pH range above 5 [141. In
contrast, calcium carbonate is much less soluble, requires an
acid pH to dissolve and, in vitro, binds phosphorus much more
slowly and incompletely than calcium acetate [14].
Achlorhydria is relatively common in patients with chronic
renal failure [201. In addition, inhibitors of gastric acid secretion
and oral antacid preparations are often prescribed. If gastric pH
is high then calcium carbonate may become less effective.
Conversely, calcium acetate binds phosphorus even more ef-
fectively at higher pH.
To the extent the anion of the calcium salt is absorbed,
important effects on acid-base balance will ensue. Absorption
of carbonate from calcium carbonate directly alkalinizes the
ECF. Absorption of acetate will also generate HC03 when it
is metabolized. Patients with chronic renal failure generally can
tolerate large acetate loads which are infused during dialytic
therapy with acetate-containing solutions. The potential acetate
load delivered via calcium acetate ingestion would be much
smaller.
Calcium chloride is another very soluble calcium salt with in
vitro phosphorus binding characteristics similar to calcium
acetate [14]. However, this salt has at least two important
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disadvantages for clinical use. First it is a very astringent and
unpalatable salt. Second, to the extent that the chloride is
absorbed, it will produce systemic acidification [21, 22]. The
calcium which remains in the intestinal lumen, in part, com-
bines with HC03 from pancreatic secretions, forming CaCO3,
while Cl is absorbed. Excretion of the relatively insoluble
CaCO3 into the stool represents systemic alkali loss and gener-
ates a metabolic acidosis.'
Calcium citrate is another relatively soluble calcium salt
which has been used as a phosphorus binder [23, 24]. However,
citrate forms soluble complexes with metal cations such as
Ca and Alt Formation of these soluble calcium citrate
complexes decreases the availability of ionized calcium for
reaction with phosphorus. Hence, in vitro calcium citrate
dissolves rapidly but binds phosphorus poorly [141. In addition,
and of great clinical importance, citrate salts markedly increase
intestinal aluminum absorption [25—27]. This may in part result
from the formation of soluble aluminum citrate complexes
which are more readily absorbed. Citrate, and other calcium
chelators, may also open tight junctions between intestinal cells
and thereby disrupt barriers to aluminum absorption [28, 291.
This study shows calcium acetate to be a more potent
phosphorus binder than calcium carbonate in patients with
renal failure. These results confirm and extend our findings in
normal subjects [141. Equal amounts of phosphorus are bound
by smaller doses of calcium acetate compared with calcium
carbonate. Consequently, the calcium load can be reduced and
the potential toxicity of calcium salts decreased. Absorbed
acetate is rapidly metabolized to HC01 and should have no
deleterious metabolic consequences. Acetate, unlike citrate,
should not increase aluminum absorption. It is difficult to
extrapolate chronic dose requirements from the results of this
single dose study. Dose titration, using serial phosphorus
measurements, will be required. Studies addressing this issue
are in progress.
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